Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of multi-contaminant exposure in a cancer treatment center: a 2-year monitoring of molds, mycotoxins, endotoxins, and glucans in bioaerosols.
Heutte N, André V, Dubos Arvis C, Bouchart V, Lemarié F, Legendre P, Votier E, Louis MY, Madelaine S, Séguin V, Gente S, Vérité P, Garon D. Heutte N, et al. Among authors: dubos arvis c. Environ Monit Assess. 2017 Jan;189(1):31. doi: 10.1007/s10661-016-5751-z. Epub 2016 Dec 23. Environ Monit Assess. 2017. PMID: 28012082
Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.
Lesueur P, Escande A, Thariat J, Vauléon E, Monnet I, Cortot A, Lerouge D, Danhier S, Dô P, Dubos-Arvis C, Chouaïd C, Gervais R. Lesueur P, et al. Among authors: dubos arvis c. Cancer Med. 2018 Nov;7(11):5505-5513. doi: 10.1002/cam4.1825. Epub 2018 Oct 11. Cancer Med. 2018. PMID: 30311424 Free PMC article.
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).
Wislez M, Mazieres J, Lavole A, Zalcman G, Carre O, Egenod T, Caliandro R, Dubos-Arvis C, Jeannin G, Molinier O, Massiani MA, Langlais A, Morin F, Le Pimpec Barthes F, Brouchet L, Assouad J, Milleron B, Damotte D, Antoine M, Westeel V. Wislez M, et al. Among authors: dubos arvis c. J Immunother Cancer. 2022 Oct;10(10):e005636. doi: 10.1136/jitc-2022-005636. J Immunother Cancer. 2022. PMID: 36270733 Free PMC article.
[Malignant mesothelioma and constitutional BAP1 gene mutations].
Neviere Z, Berthet P, Polycarpe F, Dubos-Arvis C, Dô P, Gervais R. Neviere Z, et al. Among authors: dubos arvis c. Rev Mal Respir. 2019 Feb;36(2):241-248. doi: 10.1016/j.rmr.2017.11.014. Epub 2019 Jan 24. Rev Mal Respir. 2019. PMID: 30686559 Review. French.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
19 results